Mendlewicz J
Clinique Universitaire de Bruxelles, Hôpital Erasme, Service de Psychiatrie, Belgium.
Drugs. 1992;43 Suppl 2:32-7; discussion 37-9. doi: 10.2165/00003495-199200432-00006.
The therapeutic efficacy of fluvoxamine has been demonstrated in large numbers of patients participating in comparative double-blind placebo-controlled studies using imipramine as the active reference compound. Overall, patients treated with fluvoxamine for 4 to 6 weeks had significant amelioration of their depression compared with placebo-treated patients. More importantly, the response rate in patients with severe depression was greater than in patients with mild or moderate depression. However, several investigators have observed high placebo response rates, and in some studies there has been a similar response rate to imipramine and placebo treatment. While the high placebo response rate may have resulted from methodological problems, the issue does raise some questions that can only be resolved by further investigation.
使用丙咪嗪作为活性对照化合物的大量比较性双盲安慰剂对照研究表明了氟伏沙明的治疗效果。总体而言，与接受安慰剂治疗的患者相比，接受氟伏沙明治疗4至6周的患者抑郁症状有显著改善。更重要的是，重度抑郁症患者的缓解率高于轻度或中度抑郁症患者。然而，一些研究人员观察到安慰剂反应率较高，并且在一些研究中，丙咪嗪和安慰剂治疗的反应率相似。虽然高安慰剂反应率可能是由方法学问题导致的，但这个问题确实引发了一些只能通过进一步研究来解决的疑问。
